Hikma Pharmaceuticals will joint the FTSE 100 index, replacing Shire, FTSE Russell said Wednesday.
FTSE Russell attributed the swap to Shire’s takeover by Takeda Pharmaceutical. London-listed Hikma Pharmaceuticals was founded in Jordan, and manufactures generic medicines as well as in-licensed products.
Shares of the company are up 65% in the past 12 months. Demand of its injectable medicines was recently buoyed by a shortage in the U.S., and the company reported earnings that beat analyst expectations in its latest half-year report.
FTSE Russell said that changes to the index will be made effective from Dec. 24.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.